Associated Papers
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis.
Wildschut MHE et al.
Nature Communications, 2023
37828014 (PubMed )
Supplement: 41467_2023_42101_MOESM5_ESM.xlsx › Clinical_annotations
Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms.
Morishita S et al.
International Journal of Molecular Sciences, 2023
37629188 (PubMed )
Supplement: ijms-24-13008-s001.zip › ijms-2555672-supplementary.pdf
Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.
Maddali M et al.
Hematology/oncology and Stem Cell Therapy, 2022
Mutational spectrum and prognosis in Chinese patients with prefibrotic primary myelofibrosis.
Cheng CK et al.
Ejhaem, 2022
35846205 (PubMed )
Supplement: JHA2-3-184-s002.xlsx › All_MPN_cases
Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice.
Minakawa K et al.
Journal of Hematology & Oncology, 2021
33785036 (PubMed )
Supplement: 13045_2021_1064_MOESM7_ESM.pdf
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.
Cabagnols X et al.
Leukemia, 2015
Select a paper to view details